Drug-induced subacute cutaneous lupus erythematosus associated with nab-paclitaxel therapy
Keywords: Nanoparticle albumin-bound paclitaxel, nab-paclitaxel, subacute cutaneous lupus erythematosus, cutaneous drug reactions
AbstractDrug-induced lupus erythematosus (dile) syndromes are documented complications of chemotherapeutic agents, including paclitaxel. Subacute cutaneous lupus erythematosus (scle) is a distinct dile syndrome presenting with characteristic annular or papulosquamous skin lesions in a photosensitive distribution with associated high anti-ssa titres. Previously, dile syndromes complicating paclitaxel therapy have been attributed to polyethoxylated castor oil (Kolliphor EL: BASF, Ludwigshafen, Germany), the biologic solvent included in the drug’s original formulation (Taxol: Bristol–Myers Squibb, Montreal, QC), rather than the parent chemotherapy molecule. Here, we report a characteristic case of drug-induced scle complicating treatment with nanoparticle albumin bound (nab)–paclitaxel (Abraxane: Celgene, Summit, NJ, U.S.A.), a solvent-free taxane formulation. The pertinent English-language literature is also discussed. This case report is the first to link solvent-free paclitaxel with scle, and it suggests that the parent molecule is responsible for the reaction.
How to Cite
Lamond, N., Younis, T., Purdy, K., & Dorreen, M. (2013). Drug-induced subacute cutaneous lupus erythematosus associated with nab-paclitaxel therapy. Current Oncology, 20(5), e484-e487. https://doi.org/10.3747/co.20.1546